key: cord-0919054-8453a5gs
authors: de Mélo Silva, Mário L.; Lopes, David P.
title: Large hemorrhagic stroke after ChAdOx1 nCoV‐19 vaccination: A case report
date: 2021-07-17
journal: Acta Neurol Scand
DOI: 10.1111/ane.13505
sha: 55917ddeac08518edf308c965a5f74356fd4f653
doc_id: 919054
cord_uid: 8453a5gs

BACKGROUND: The anti‐COVID‐19 vaccines are new, and we should be alert of potential adverse effects of them. AIMS OF THE STUDY: To report a case of a large hemorrhagic stroke 5 days after ChAdOx1 nCoV‐19 vaccination. METHODS: Clinical, imaging, and laboratory data of a patient with stroke admitted to our emergency department. RESULTS: A woman, 57 years old, took the first dose of the ChAdOx1 nCoV‐19 vaccine and shortly thereafter presented mild systemic symptoms and started on aspirin. On day 5, she had a sudden onset of sweating and paleness, which has followed by left hemiparesis, vomiting, and somnolence. Computed tomography showed a large right deep frontal lobe parenchymal hematoma with the inundation of the entire ventricular system. Platelets count, fibrinogen, prothrombin time, and D‐dimer were normal. Digital subtraction angiography did not show any signs of thrombosis or aneurysms in brain circulation. CONCLUSIONS: Clinicians should be aware of cerebrovascular adverse effects of ChAdOx1 nCoV‐19, including out‐of‐context of vaccine‐induced immune thrombotic thrombocytopenia.

of the vaccine. On day 5, she had a sudden onset of sweating and paleness, which has followed by left hemiparesis, vomiting, and somnolence. She came to the emergency room with a Glasgow Coma Scale of 7 and required orotracheal intubation; blood pressure was 160 × 90 mmHg. Computed tomography showed a large right deep frontal lobe parenchymal hematoma with the inundation of the entire ventricular system (Figures 1 and 2 ). Platelets count, fibrinogen, prothrombin time, and D-dimer were normal. Digital subtraction angiography did not show any signs of thrombosis or aneurysms in brain circulation. She underwent hematoma drainage and external ventricular drain, but intracranial pressure kept raising and she underwent decompressive craniectomy. We also did not find any signs of thrombosis in other sites. At the time of submitting this report (day 15), she is left hemiparetic, capable of obeying simple tasks, and on tracheostomy.

Brain hemorrhage in the context of VITT has been described, 4 but primary hemorrhagic stroke following ChAdOx1 nCoV-19 vaccination in a patient without thrombocytopenia, coagulation disorder, or risk factors was not. It is worth noting that this case presents an atypical site and uncommonly large volume for stroke, which raises concerns about its pathogenesis. Data 3 suggested that, besides thrombosis, there might also be a greater risk of bleeding events related to that vaccine.

Although we cannot claim causality in this report, it is important to keep surveillance on the adverse effects of vaccines.

Authors thank patient's family members for consent with this publication.

The authors have no conflict of interests to declare.

MLM conceptualized, acquired data, and wrote the draft of the report. DPL acquired data and reviewed the report for scientific content. All the authors had access to the data and a role in writing the manuscript.

Informed consent was obtained from family of the patient prior writing this case report. 

The potential neurological effect of the COVID-19 vaccines: a review

Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination